Kazia TherapeuticsのIPO年
Kazia TherapeuticsのIPO年は何ですか。
Kazia Therapeutics LimitedのIPO年は1994です。
IPO年の定義は何ですか。
新規公開株 (IPO)は、企業の株式を通常は機関投資家に販売し、順番に証券取引所で一般市民に販売する株式公開の一種です。
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
ASXのセクタHealth CareにおけるIPO年の企業と比べるKazia Therapeutics
Kazia Therapeuticsは何をしますか。
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Kazia Therapeuticsと類似のipo年
- Sinopec Shanghai Petrochemical CoのIPO年は1993です。
- Delaware Investments Minnesota Municipal Income Fund II IncのIPO年は1993です。
- Delaware Investments Colorado Insured Municipal Income Fund IncのIPO年は1993です。
- Western Asset Municipal Partners Fund IncのIPO年は1993です。
- Nuveen Maryland Quality Municipal Income FundのIPO年は1993です。
- Enel Americas SAのIPO年は1993です。
- Kazia TherapeuticsのIPO年は1994です。
- Hanover Insurance IncのIPO年は1995です。
- Atlanticus CorpのIPO年は1995です。
- Integra Lifesciences CorpのIPO年は1995です。
- Telkom Indonesia (Persero) Tbk PTのIPO年は1995です。
- Myriad GeneticsのIPO年は1995です。
- Redwood TrustのIPO年は1995です。